Melanoma Clinical Trials in Ohio

Showing 141-160 of 257 trials

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.

Recurrent Melanoma

Kari Kendra8 participantsStarted Aug 2014

Columbus, Ohio, United States

COMPLETEDNA32 miles

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

NCT00297895

Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.

Melanoma

Saint John's Cancer Institute1,939 participantsStarted Sep 2004

San Diego, California, United States • Santa Monica, California, United States • Colorado Springs, Colorado, United States +60 more locations

PreviousPage 8 of 13Next

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma Trials in Other Cities

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Safety Study of SEA-CD40 in Cancer Patients

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Engaging Moms on Teen Indoor Tanning Through Social Media

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of PLX2853 in Advanced Malignancies.

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Ohio